Rege Nephro

The company researches and develops therapeutics for kidney disease, including an iPS cell-derived nephron progenitor cell therapy for chronic kidney disease and a drug candidate for autosomal dominant polycystic kidney disease, addressing lack of curative treatments and progression to dialysis or transplant. It serves healthcare providers and pharmaceutical partners focused on nephrology and regenerative medicine. It delivers therapies through cell differentiation, purification and culture processes and subcapsular delivery intended to provide localized paracrine effects.

Key features

• iPS cell-derived nephron progenitor cell therapy for CKD
• Novel therapeutic development for ADPKD (RN-014)
• Purification and culture methods for nephron progenitors
• Subcapsular delivery via specialized device
• Paracrine effect to support damaged kidney
• Manufacturing process scale-up collaboration